Fansidar-resistant Plasmodium falciparum infection from Tanzania.
Since 1978 several cases of chloroquine-resistant falciparum malaria have been reported from East Africa (Petterson et al., 1981). Sulfadoxine-pyrimethamine (Fansidar) has been advised by W.H.O. (Wkly Epidem. Rec., 1982) for therapeutic management of these patients. We describe here a non-immune female expatriate from Tanzania suffering from falciparum malaria, which was resistant to chloroquine (R II-III). She had been working as a medical technician in the Morogoro region, a hyperendemic malarious area. After being treated with Fansidar she was transferred to the Netherlands where a recrudescence developed. She was then treated with a combination of quinine and tetracycline which resulted in the clearance of the parasitaemia. This is the third report of Fansidar-resistant falciparum malaria from Tanzania in the Netherlands (de Geus et al., 1982; Timmermans et al., 1982).
D000328:Adult; D000962:Antimalarials / Q000627:therapeutic use*; D002738:Chloroquine / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D010963:Plasmodium falciparum / Q000187:drug effects*; D011739:Pyrimethamine / Q000627:therapeutic use*; D013413:Sulfadoxine / Q000627:therapeutic use*; D013424:Sulfanilamides / Q000627:therapeutic use*
D000962:Antimalarials; D004338:Drug Combinations; D013424:Sulfanilamides; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D002738:Chloroquine; D011739:Pyrimethamine